NLRC4 and bacterial infectious disease: In addition to ongoing research on NAIP/NLRC4 mutations contributing to both bacterial infections and sterile inflammation in autoimmune and inflammatory diseases (84), the interplay between NLRC4 and PUFA metabolites may open another window for developing new therapeutic strategies.